New study opens the door to learning more about an important driver of breast cancer 13 Feb 2024 Through innovative exploratory work, scientists have identified a new way to study proteins that are involved in the development of the majority of breast cancers. Find out more Show/Hide
‘Molecular glue degrader’ reaches cancer trial following ICR research programme 23 Feb 2023 The biotechnology company Monte Rosa Therapeutics – originally a spin-out from research at The Institute of Cancer Research, London – has announced that the first patient has received their ‘molecular glue degrader’ drug as part of a clinical trial in oncology. Find out more Show/Hide